Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
Clinical trial NCT02761694 · TERMINATED
Trial details
- NCT number
- NCT02761694
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-26
- Primary completion
- 2021-03-10
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.